Surrey Heartlands

Joint Formulary & PAD

Testosterone - Transgender Health - Children and Young People

You are here : Home > Formulary Search > Testosterone - Transgender Health - Children and Young People

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Gel
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Un
Restrictions / Comments :

Documentation

Webpage
Prescribing of Gender Affirming Hormones in Children and Young People - NHSE Commissioning Policy - Mar 24
Webpage
Puberty Supressing Hormones - NHSE Clinical Policy - Mar 2024
Education material (for healthcare personnel)
Gender Identity Training and Information Resources

PAD Profile

ChemicalSubstance :
Testosterone
Indication :
Transgender Health - Children and Young People
Group Name :
Keywords :
gender reassignment, gender re-assignment, gender identity clinics, GICs, gender incongruence, sex change, transgender, hormonal therapy, masculinisation, transsexuals, hormonal treatment, gender dysphoria
Brand Names Include :
Tostran, Testogel, Sustanon 250
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Transgender Health - Children and Young People
Supporting Documents :
3

Other Indications

Below are listed other indications that Testosterone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Transgender Health - Children and Young People.

Committee Recommendations (2)

05 Jun 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for gender affirming hormones in children and young people.  This applies to recommendations from both NHS and private providers subject to appropriate shared care protocols being in place.

The following guidance has also been updated:

  • Primary care prescribing guidance, for people who access Gender Identity Services.
  • NHSE guidance on prescribing and dispensing restrictions for puberty blockers and gender affirming hormones

 

07 Feb 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Health System Area Prescribing Committee (APC) has agreed that topical testosterone should be prescribed generically, ideally using Drug Tariff descriptions.